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PhenotypeSummary Cytogenetic abnormalities in B-cell posttransplant lymphoproliferative disorders (PTLD) have
not been well characterized. We thus performed cytogenetic analysis of 28 cases of B-cell PTLD,
1 infectious mononucleosis (IM)–like lesion, 9 polymorphic PTLD, 17 monomorphic PTLD, and
1 classical Hodgkin lymphoma (HL), and correlated the karyotypic findings with the phenotype, Epstein-
Barr virus infection status, and clinical outcome. Karyotypes of 19 cases of posttransplant florid follicular
hyperplasia (FFH) were also analyzed. Informative karyotypes were obtained in 20 (71.4%) of 28 PTLDs
and 18 (94.7%) of 19 FFHs. Clonal karyotypic abnormalities were detected in 13 (65%) of 20 PTLDs,
including 9 (75%) of 12 monomorphic PTLDs, 2 (33.3%) of 6 polymorphic PTLDs, 1 IM-like lesion, and
1 HL, and 2 (11.1%) of 18 FFHs. Recurrent chromosome breaks at 1q11-21 (n = 6, including 1 FFH),
14q32 (n = 3, including 1 FFH), 16p13 (n = 3), 11q23-24 (n = 2), and 8q24 (c-MYC) (n = 2); gains of
chromosome 7 (n = 4), X (n = 3), 2 (n = 3), 12 (n = 2); and loss of chromosome 22 (n = 2, including 1 IM-
like lesion) were identified. The presence of cytogenetic abnormalities did not correlate with PTLD
phenotype, Epstein-Barr virus infection, or clinical outcome. We describe novel karyotypic aberrations in
PTLD and report clonal cytogenetic abnormalities in posttransplant FFH and an IM-like lesion for the first
time. Our findings provide validation of the currentWorld Health Organization classification of PTLD and
also suggest incorporation of FFH as the earliest recognizable precursor of PTLD.
D 2007 Elsevier Inc. All rights reserved.Elsevier Inc. All rights reserved.
(G. Bhagat).1. Introduction
B-cell posttransplant lymphoproliferative disorders
(PTLD) comprise a spectrum of lymphoid proliferations
ranging from early lesions, represented by plasma cell
hyperplasia (PH) and infectious mononucleosis (IM)–likeHuman Pathology (2007) 38, 315–325
E. Vakiani et al.316proliferations, which are mostly polyclonal, to monomorphic
PTLD (M-PTLD) that are usually monoclonal proliferations
of mature B cells or plasma cells [1]. The majority of B-cell
PTLD are associated with Epstein-Barr virus (EBV) infec-
tion, but EBV-lymphoid proliferations are not uncommon,
occurring late after organ transplantation [2].
The current World Health Organization (WHO) classi-
fication represents a refinement of the prior classification
schemes for PTLD [3-5], although the precursor product
relationship between early lesions or polymorphic PTLD
(P-PTLD) and distinct subsets of M-PTLD is unclear at
present. Recent studies [6,7] have also suggested that
adenotonsillar hypertrophy, histologically characterized by
florid follicular hyperplasia (FFH), might represent a
precursor to PTLD. However, an association of FFH with
currently recognizable types of PTLD has not been
demonstrated [8] and FFH is not recognized as a precursor
lesion in the current WHO classification [1].
Many studies have elucidated the cytogenetic and
molecular underpinnings of a variety of B-cell non-Hodgkin
lymphomas (B-NHL) occurring in immunocompetent indi-
viduals [9-13], but there is limited information regarding
genetic alterations in PTLD. Mutations in protooncogenes
or tumor suppressor genes, for example, c-MYC, N-RAS,
BCL6, and p53 [4,14] have been reported, mostly in
M-PTLD, and mutations of BCL6 have been associated
with a worse clinical outcome [14]. Aberrant somatic
hypermutation leading to mutations of protooncogenes
c-MYC, PAX5, and RhoH/TTF has also recently been
described in M-PTLD [15]. Data regarding chromosomal
abnormalities in PTLD consist of case reports [16-20] and
only 2 recently published series [21,22].
Thus, the aim of our study was to determine the nature
and frequency of karyotypic abnormalities in B-cell PTLD
and FFH of adenotonsillar, nodal, and extranodal lymphoid
tissue diagnosed at our institute over a 9-year period. We
also correlated the karyotypic findings with the phenotype
of these lymphoproliferations, results of B-cell clonality and
EBV infection, and the clinical outcome.2. Materials and methods
2.1. Case selection and clinical parameters
We searched our cancer cytogenetics database to retrieve
cases of B-cell PTLD and lymphoid tissue showing FFH
submitted for karyotype analysis, over a 9-year period
(1997-2005). Data regarding immunosuppressive regimens,
antiviral capsid antigen IgG (IgG-VCA) titers, polymerase
chain reaction (PCR)–based quantification of EBV viral
load, and clinical outcomes were obtained from our hospital
information system; IgG-VCA titers greater than 1:40 were
considered positive and 5-fold or greater increase of EBV
viral copies, above the PCR limit of detection (200 copies
per milliliter), was considered evidence of viral reactivation.2.2. Morphologic and phenotypic characterization
Posttransplant lymphoproliferative disorders were cate-
gorized according to the current WHO classification [1]
using hematoxylin and eosin–stained, formalin-fixed, par-
affin-embedded sections. In addition, PTLD were defined
as having a germinal center (GC) phenotype if they had
the profile BCL6+, MUM1, CD138, and as post-GC
if they were BCL6, MUM1+, CD138 or BCL6,
MUM1+, CD138+.
2.3. Immunohistochemistry, in situ hybridization,
and flow cytometry
The panel of primary antibodies used for immunohisto-
chemical staining included CD20, BCL6, MUM1, CD3,
CD21, CD138 (DAKO, Carpinteria, Calif), BCL2 (Bio-
genex, San Ramon, Calif), CD10 (Novocastra, Burlingame,
Calif), and j and k (Cell Marque, Hot Springs, Ariz).
Staining was performed after moist heat-induced antigen
retrieval using an autostainer (Universal Staining System,
DAKO) according to standard methods. The Envision Plus
kit (DAKO) was used for detection with 3,3V-diaminoben-
zidine as the chromogen. In situ hybridization for EBV-
encoded small RNAs (EBER) was performed in all cases
using the supplied protocol (INFORM EBER, Ventana,
Tucson, Ariz). The frequency of EBER+ cells was scored in
a semiquantitative manner by averaging the number of
positive cells in 10 random high power fields (HPF).
Three- or 4-color flow cytometric analysis (FACScan;
Becton Dickinson, San Diego, Calif) was performed
according to standard methods and data analyzed using
the Cell Quest software (Becton Dickinson). Antibodies
used included CD45, CD19, CD20, CD10, CD3, IgM, IgG,
IgA, IgD, j, and k (BD Biosciences, San Diego, Calif).
2.4. Immunoglobulin heavy chain gene
rearrangement analysis
Polymerase chain reaction analyses to detect immuno-
globulin heavy chain (IgH) gene rearrangements were
performed using DNA extracted from formalin-fixed,
paraffin-embedded tissue using consensus primers for the
heavy chain framework region 3 and the joining region,
followed by polyacrylamide gel electrophoresis after het-
eroduplex formation, as previously described [23].
2.5. Giemsa-band karyotype, fluorescence in situ
hybridization, and spectral karyotype analysis
Giemsa banding was performed on metaphase prepara-
tions obtained after overnight cell culture (12-15 hours)
without mitogen stimulation using standard methods, and
the karyotype was described according to ISCN [24].
Fluorescence in situ hybridization (FISH) analyses were
performed on methanol–acetic acid fixed cells (14 cases)
using IGH (n = 12), BCL6 (n = 5), BCL2 (n = 3), MYC
(n = 2), and MALT1 (n = 1) dual-color break-apart probes
Analysis of B-cell PTLD 317(VYSIS, Downers Grove, Ill), according to standard
protocol; 200 to 500 cells were analyzed. Fluorescence
signals were captured after counterstaining with DAPI using
the Cytovision Imaging system attached to a Nikon Eclipse
600 microscope (Applied Imaging, Santa Clara, Calif).
Spectral karyotype (SKY) was performed on metaphase
preparations using the human SKYPaint kit (Applied
Spectral Systems, Carlsbad, Calif) according to the manu-
facturer’s protocol.
2.6. Statistical analysis
Fisher exact test and Student t test were performed to
evaluate differences between datasets, as applicable, and a
P value less than .05 was considered significant.3. Results
3.1. Clinical characteristics
Tonsil and/or adenoid (n = 16) and lymph node (n = 2)
specimens with FFH from 18 of 19 patients (8 males,
10 females; age, 2-60 years; median, 3.5 years; mean,
8.4 years) had analyzable metaphases. These patients had
undergone liver (n = 15), kidney (n = 1), or heart (n = 2)
transplantation. The median time from transplant to diag-
nosis was 35 months (range, 7-96 months; mean,
41.8 months). None of the patients required reduction in
immunosuppression or chemotherapy, and 16 of 18 patients
are currently alive (range, 2-41 months; median, 14 months;Table 1 Clinical characteristics of patients with cytogenetic abnorm
Patient Age (y) Sex Site Diagnosis EBV
serolo
pretra
1 4 M Tonsils,
adenoids
FFH Positi
2 2 F Tonsils FFH Negat
3 9 F Tonsils,
adenoids
early lesion IM-like Positi
4 3 F Lymph node P-PTLD Positi
5 21 M Lymph node P-PTLD Negat
6 60 M Soft tissue M-PTLD–MZBCL Positi
7a 11 F Pleural fluidb M-PTLD–DLBCL, c Negat
7b Lymph nodeb
8 54 M Lymph node M-PTLD–DLBCL, c ND
9 72 M Bone marrow M-PTLD–DLBCL, i Positi
10 64 M Pleural fluid M-PTLD–DLBCL, c ND
11 76 M Nasal mucosa M-PTLD–DLBCL, p ND
12 25 M Cecum M-PTLD–BL Negat
13 15 M Tonsils,
adenoids
M-PTLD–PLL Negat
14 4 F Lymph node cHL Positi
Abbreviations: c, centroblastic; i, immunoblastic; p, plasmablastic; cHL, classic
DI, decreased immunosuppression; CT, chemotherapy; RT, radiation; LTF, lost
a Died of gastric cancer.
b Specimens from the same patient obtained 1 week apart.mean, 17.3 months) since diagnosis; 2 were lost to follow-
up. None of the patients developed PTLD after FFH;
however, 2 had developed M-PTLD, in the stomach and
in tonsils and right cervical lymph node, 2 and 6 years
before FFH of tonsils and right cervical lymph node,
respectively. Cytogenetic analyses of PTLD were not
performed, and specimens with FFH from both patients
had normal karyotypes.
Twenty-eight specimens, including nodal (n = 8), extra-
nodal (n = 15), and adenotonsillar tissue (n = 5), from
27 patients with B-cell PTLD, including 1 IM-like lesion,
1 classic Hodgkin lymphoma (HL), 9 P-PTLD, and
17 M-PTLD, were submitted for cytogenetic analysis.
Monomorphic PTLD from 2 different sites (obtained 1 week
apart) were analyzed for 1 patient (no. 7, Table 1).
Analyzable metaphases were obtained in 20 (71.4%) of
28 PTLD involving nodal (n = 7), extranodal (n = 10), and
adenotonsillar tissue (n = 3) from 19 patients. One patient
had an IM-like lesion (no. 3, Table 1), 6 had P-PTLD
(3 males, 3 females; median age, 14 years; mean age,
19.3 years; range, 3-56 years), 11 had M-PTLD (10 males,
1 female; median age, 58 years; mean age, 48.8 years; range,
11-76 years), and 1 had HL (no. 14, Table 1). Patients with
P-PTLD had undergone heart (n = 3), liver (n = 1), kidney
(n = 1), and lung (n = 1) transplantation, 3 to 144 months
previously (median, 14 months; mean, 29.3 months). Treat-
ment consisted of decrease in immunosuppression, either
alone (n = 1) or in combination with chemotherapy (n = 4),
rituximab (n = 3), and radiation (n = 1). Five (83.3%) of












ve Liver 43 NA A (11 mo)
ive Liver 21 NA A (41 mo)
ve Heart 104 None A (12 mo)
ve Liver 35 DI, CT, rituximab LTF
ive Kidney 6 DI, CT, rituximab A (4 mo)
ve Kidney 96 DI, rituximab Da (36 mo)
ive Liver 83 DI, rituximab D (1 mo)
Liver 177 CT A (2 mo)
ve kidney 120 CT D (18 mo)
kidney 54 CT, rituximab D (18 mo)
heart 144 DI, RT A (35 mo)
ive kidney 93 CT A (6 mo)
ive heart 143 CT A (2 mo)
ve heart 18 CT A (51 mo)
Hodgkin lymphoma; A, alive; D, dead; ND, not done; NA, not applicable;
to follow-up.
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died 6 months postdiagnosis from infectious complications.
Patients with M-PTLD had undergone kidney (n = 6), heart
(n = 4), and liver (n = 2) transplantation (1 patient received a
combined kidney-liver transplant), 3 to 177 months previ-
ously (median, 96 months; mean, 96.8 months). Ten patients
received chemotherapy, 3 of whom also received rituximab,
and 1 was treated with radiation alone. Four (36.4%) of
11 patients are alive 2 to 35 months (median, 4 months;
mean, 11.3 months) after diagnosis, and 7 patients died from
progression of their disease (n = 5), sepsis (n = 1), or gastric
cancer (n = 1), 1 to 36 months (median, 4 months; mean,
11.6 months) after diagnosis.
Two patients (nos. 4 and 3, Tables 1 and 2) had
adenotonsillar FFH, 11 months and 8 years before diagnosis
of PTLD, respectively. One patient (no. 13, Table 1)
developed M-PTLD involving tonsils and adenoids,
8.5 years after PH at the same site. Cytogenetic analyses
on specimens with FFH and PH were not performed.
3.2. Morphology and phenotype
All tonsils and adenoids (and 2 lymph nodes) diagnosed
as FFH (Fig. 1A) showed markedly enlarged germinal
centers (CD10+, BCL6+, BCL2) containing numerous
tingible-body macrophages and expanded follicular dendrit-
ic cell meshworks (CD21+). A variable number of follicles
showed blurring of the dark zone–light zone boundary
and attenuation or loss of the mantle zones. Interfollicular
areas were only mildly expanded by small lymphocytes,
scattered immunoblasts, and small clusters of polytypic
plasma cells.
The IM-like lesion (Fig. 1D) showed large secondary
follicles similar to those observed in FFH and a moderate to
marked interfollicular expansion due to increased numbers of
polytypic plasma cells, small lymphocytes, histiocytes, and
scattered or small clusters of immunoblasts. Diffuse poly-
typic plasma cell infiltrates with absent or rare reactive
follicles were diagnosed as PH. P-PTLD (Fig. 1F) showed
scattered or small clusters of large centroblasts or immuno-
blasts that had a post-GC phenotype (BCL6, MUM1+,
CD138) in the background of small lymphocytes, histio-
cytes, and polytypic plasma cells. Monomorphic PTLD
consisted of monomorphic populations of centroblasts,
immunoblasts, plasmablasts, or plasma cells, which were
classified as diffuse large B-cell lymphoma (DLBCL) (n = 9),
Burkitt lymphoma (n = 1), marginal zone B-cell lymphoma
(MZBCL) (n = 1), and plasmacytoma-like lesion (PLL)
(n = 1). Three (33.3%) of 9 DLBCL, all centroblastic
(Fig. 1H), and the BL had a GC phenotype (BCL6+,
MUM1, CD138) and 6 (66.7%) of 9 DLBCL had a
post-GC phenotype: 4 centroblastic and 1 immunoblastic
(BCL6, MUM1+, CD138) and 1 plasmablastic (BCL6,
MUM1+, and CD138+). The MZBCL (BCL6, MUM1+,
CD138) and PLL (BCL6, MUM1+, CD138+) had post-
GC phenotypes.3.3. Epstein-Barr virus infection
3.3.1. Florid follicular hyperplasia
The occurrence of FFH did not correlate with recent EBV
infection (EBV seroconversion predated FFH by N1 year in
all cases) and none had an IM-like illness. Epstein-Barr
virus–infected lymphocytes were noted in 66.7% FFH and
viral reactivation was only rarely observed.
No EBER+ lymphocytes were detected in 6 FFH, and
rare, single scattered EBER+ small lymphocytes (b1 EBER+
lymphocytes/10 HPF) were seen in 1 case. Increased
numbers of small EBER+ lymphocytes (range, 1-54/HPF)
were seen in the interfollicular areas in 11 (61.1%) of
18 FFH (Fig. 1B); large EBER+ lymphocytes were rare in
all cases. Occasional EBER+ lymphocytes (range, 1-8/HPF)
were seen in 2 (9%) of 22 and 5 (12.5%) of 40 GC in 3 cases
and numerous EBER+ cells (up to 100/HPF) were observed
in 6 (19.4%) of 31 GC in 1 case. These findings are similar
to previous observations in posttransplant patients [8] and
healthy individuals with prior EBV infection [25].
Pre- and posttransplant IgG-VCA titers and PCR-based
EBV viral load quantification data were available for
10 (55.6%) of 18 FFH patients. Six patients with FFH were
EBV seronegative before transplantation (age range,
2-7 years; median, 2.5 years; mean, 3.7 years), and 4 of
them seroconverted after transplantation, 1 to 4 years before
development of FFH; 3 of the latter had 3 to 12 EBER+
lymphocytes/HPF in interfollicular areas, and no EBER+
lymphocytes were detected in 1 case. Four patients with
FFH who were EBV seropositive pretransplantation (age
range, 3-60 years; median, 5.5 years; mean, 18.5 years)
showed 1 to 8 EBER+ lymphocytes/HPF in interfollicular
areas; rare (1-8/HPF) EBER+ GC cells were seen in
2 cases. Viral reactivation was only observed in 2 of
10 patients by PCR (1100 and 1900 copies per milliliter)
who had 3 and 9 EBER+ lymphocytes/HPF in interfollicular
areas, respectively.
3.3.2. Posttransplant lymphoproliferative disorders
Thirteen of 20 PTLD showed evidence of EBV infection
and occurrence of EBV+ PTLD showed no correlation with
the patients’ EBV serologic status before transplantation.
Epstein-Barr virus–positive PTLD included 4 (66.7%) of
6 P-PTLD (Fig. 1G), 7 (58.3%) of 12 M-PTLD, 1 IM-like
lesion, and 1 HL. The IM-like lesion showed only scattered
small EBER+ cells (5/HPF) in the interfollicular areas
(Fig. 1E).
Pre- and posttransplant IgG-VCA titers were available
for 12 (63.2%) of 19 patients, and PCR-based EBV viral
load quantification was performed in 8 (50%) of 19 patients.
Four patients with PTLD were EBV seronegative before
transplantation (age range, 4-25 years; median, 16 years;
mean, 15.3 years) and all of them seroconverted after
transplantation; 2 of these patients developed EBV+ and
2 EBV PTLD. Of the 8 PTLD patients who were EBV
seropositive before transplantation (age range, 2-72 years;
median, 16 years; mean, 29.1 years), 5 developed EBV+
Table 2 Molecular, phenotypic, and cytogenetic characteristics of cases with karyotypic abnormalities
Case Diagnosis Phenotype EBER G-banded karyotype FISH Clonality
PCR Flow
cytometry
1 FFH NA Positivea 46,XY,t(1;14)(q21;q32)[3]/46,XY[17] IgH T NC P
2 FFH NA Negative 47,XX,+1mar[3]/46,XX[17] ND NC ND
3 IM-like lesion NA Positiveb 46,XX,22.+1mar[7]/46,XX[13] ND NC P
4 P-PTLD Post-GC Positive 47,XX,t(1;3)(p36;p21),+1mar[cp18]/46,XX[2] ND C ND
5 P-PTLD Post-GC Positive 46,XY,ins(11;?)(q23.1;?)[3]/46,XY[9] IgH NT, BCL6 NT NC P
6 M-PTLD–
MZBCL
Post-GC Positive 47,XY,+2,del(7)(q33)[18] ND C P
7a M-PTLD–
DLBCL, cc
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Abbreviations: NC, no clonal band obtained; P, polyclonal; C, clonal; T, translocation present; NT, no translocation detected; ND, not done; NA, not applicable.
a An average of 8 EBER+ cells/HPF were present in the interfolicular areas and 2 of 22 GC had 2 to 8 EBER+ cells/HPF.
b Only scattered (5/HPF) EBER+ cells were seen in interfollicular areas.
c Same results for both specimens.
Analysis of B-cell PTLD 319PTLD (including an early lesion) and 3 EBV PTLD. Viral
reactivation was not observed in any patient, where data
were available. The mean time from transplant to develop-
ment of EBV PTLD was longer than that of EBV+ PTLD
(102.7 versus 60.6 months, P = .11), as previously reported
[2], although the difference was not statistically significant.
3.4. B-Cell clonality
Fifteen (78.9%) of 19 PTLD tested, including 5 (83.3%)
of 6 P-PTLD and 10 (90.9%) of 11 M-PTLD, had evidenceof a clonal B-cell population, 7 of 15 by flow cytometry and
10 of 18 by PCR for IgH gene rearrangement. None of the
FFH cases showed a clonal product by PCR or light chain
restriction by flow cytometry.
3.5. G-Banded karyotype, FISH, and SKY analysis
Fifteen (83.3%) of 18 FFH with analyzable metaphases
had a normal karyotype, 2 (11.1%) had clonal karyotypic
abnormalities (Table 2), and 1 (5.6%) had a nonclonal
translocation t(7;11)(q31.2;q24). In 1 patient (no. 1), the
Fig. 1 Examples of posttransplant lymphoproliferations with karyotypic abnormalities. Florid follicular hyperplasia of tonsil (case 1,
Table 2): expanded GC with attenuated mantle zone (A), scattered EBER+ cells are present in interfollicular areas (asterisk indicates GC) (B),
FISH with IGH break-apart probe shows a metaphase spread with 2 red and green (split) signals consistent with a biallelic translocation (C),
partial G-banded karyotype (C, inset) shows t(1;14)(q21; q32). Infectious mononucleosis–like lesion in tonsil (case 3, Table 2): expanded GC
and interfollicular areas (D), rare EBER+ cells are seen in interfollicular areas (asterisk indicates GC) (E), partial G-banded karyotype
(E, inset) shows loss of 1 copy of chromosome 22 and presence of a marker chromosome (arrowhead). Polymorphic PTLD (case 4): scattered
large centroblast-like cells amidst plasma cells, small lymphocytes, and histiocytes (F), which are EBER+ (G); partial G-banded karyotype
(G, inset) shows t(1;3)(p36;p21) and a marker chromosome (arrowhead). Monomorphic PTLD (DLBCL) (case 10, Table 2) with
centroblastic morphology (H): SKY (I) shows complex karyotypic abnormalities, including t(2;3)(p11.2;q27).
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Analysis of B-cell PTLD 321same karyotypic abnormality was detected in the adenoids
and tonsils.
Normal karyotypes were observed in 7 (35%) of
20 PTLD with analyzable metaphases, including 3 (25%)
of 12 M-PTLD and 4 (66.7%) of 6 P-PTLD. Clonal
karyotypic abnormalities were detected in 13 (65%) of
20 PTLD, including 9 (75%) of 12 M-PTLD, 2 (33.3%) of
6 P-PTLD (Fig. 1G), 1 of 1 IM-like lesion (Fig. 1E), and
1 of 1 HL (Table 2). All P-PTLD, FFH, and the IM-likeFig. 2 Chromosome ideograms illustrating genomic aberrations in th
represents a gain (red) or loss (green) of chromosomes or chromosomal
PTLD, and M-PTLD, respectively).lesion exhibited simple (b3) karyotypic abnormalities,
whereas 2 (22.2%) of 9 M-PTLD had simple karyotypic
abnormalities and 7 (77.8%) of 9 M-PTLD and the HL had
complex karyotypes.
A total of 100 chromosome aberrations (Fig. 2) were
found, which include 78 structural abnormalities (4.9 break-
points per case, each marker chromosomes representing
2 breakpoints) and 22 numerical abnormalities (1.4 per
case). Of the numerical abnormalities, gain of chromosomese various types of posttransplant lymphoproliferations. Each line
regions (stars, squares, and triangles denote breakpoints in FFH, P-
Table 3 Correlation of PTLD cytogenetic abnormalities with
EBV infection, phenotype, clonality, clinical outcome, and time
since transplant








EBER+ n = 9 (n = 5) n = 4 .65 (1)
EBER n = 4 (n = 3) n = 3
EBV seropositivea n = 5 (n = 4) n = 3 1 (1)
EBV seronegativea n = 4 (n = 4) n = 1
Phenotype
GC n = 3 (n = 2) n = 1 1 (1)
Post-GC n = 8 (n = 5) n = 6
Clonality
Clonalb n = 8 (n = 6) n = 7 .24 (0.22)
No evidence
of clonalityb
n = 4 (n = 1) n = 0
Clinical outcome
Dead n = 4 (n = 3) n = 4 .38 (0.58)





53.4 mo .04 (0.76)
a Before transplantation.
b By PCR analysis and/or flow cytometry.
E. Vakiani et al.322was more frequent (n = 15) than loss (n = 7). Trisomy 7
(n = 4), X (n = 3), 2 (n = 3), and 12 (n = 2) were recurrent
chromosome gains, whereas chromosome 22 (n = 2) was
the only recurrently lost chromosome. In addition, a
complete or partial gain of 1q region was observed in
5 cases. Of the clonal structural abnormalities, chromosome
breaks involving the 1q11-q21 region were the most
frequent (n = 6, including 1 FFH), followed by 16p13
(n = 3), 14q32 (n = 3, including 1 FFH), and 11q23-24
(n = 2). Nonrecurrent translocation breaks at 3q27 and
18q21 were seen in 1 case each.
Fluorescence in situ hybridization analysis using a
variety of break-apart probes was performed in 14 cases
(6 with abnormal karyotypes, 6 with normal karyotypes,
and 2 with no analyzable metaphases). Fluorescence in situ
hybridization analysis using the IGH probe confirmed
translocation of this locus in 2 of 3 cases with 14q32
translocations, including a biallelic translocation in 1 FFH
(Fig. 1C). Ten additional cases tested, including 2 cases
without analyzable metaphases, did not show IGH trans-
locations. In 1 M-PTLD with a 3q27 translocation, FISH
analysis using the BCL6 probe confirmed translocation of
BCL6; no abnormalities were detected in 4 other cases,
including 1 case without analyzable metaphases. Fluores-
cence in situ hybridization analysis using the BCL2 probe
did not show translocation of this gene in 3 cases, including
1 case with an add(18)(q21) marker chromosome. The
latter was also negative for MALT1 translocation. Fluores-
cence in situ hybridization analysis using the MYC probe
showed translocation in 2 BL tested including 1 without
analyzable metaphases.
Ten of 16 lymphoproliferations with abnormal karyo-
types by G-banding had some unidentifiable karyotypic
changes and/or marker chromosomes. Spectral karyotype
analysis was performed on 2 such PTLD (patients 10 and
11) in an attempt to identify uncharacterized aberrations.
Spectral karyotype analysis identified add(16)(p13), seen on
G-banding in 1 M-PTLD case (no. 11), as der(16)t
(12;16)(p11.2;p13); however, a marker chromosome seen in
a small subclone could not be identified because of lack of
additional metaphases with this abnormality. Another
M-PTLD (patient 10) showed a highly complex karyotype
by G-banding: 54,XY,+X, t(1;4)(q12;p15.3),+i(1)(q10),
t (2;3) (p11.2;q27) ,add(2)(p11.2) ,dup(5)(q31q35),
+7,+8,+12,der(14)t(14;14)(q13;q21),add(16)(q21),add(16)
(q22),+add(16)(q23),17,19,+20x2,der(21)t(11;21)
(q13.1;p11.2),+22[15]. Many of the markers that could not be
characterized by G-banding were identified by SKY analysis
(Fig. 1I, modified SKY karyotype is shown in Table 2).
3.6. Correlation of cytogenetic abnormalities
with EBV infection, phenotype, B-cell clonality,
and clinical outcome
There was no significant association between EBV
infection and the presence of karyotypic aberrations inFFH. Cytogenetic abnormalities were present in EBER
and EBER+ FFH (1/7 [14.3%] versus 1/11 [9.1%], P = 1.0)
and occurred in both patients who were EBV seropositive or
seronegative before transplantation (1/4 [25%] versus 1/6
[16.7%], P = 1.0). Posttransplant lymphoproliferative
disorders with chromosomal abnormalities occurred signif-
icantly later posttransplant compared to those with normal
karyotypes (Table 3) and 14q32 abnormalities were only
seen in PTLD with a GC phenotype (2/3 GC versus 0/8 post-
GC, P = .05). Although 16p13 abnormalities were only
found in PTLD with a post-GC phenotype, the results did
not reach statistical significance (0/3 GC versus 3/8 post-
GC, P = .49), presumably because of the small sample size.
Overall, the presence (or complexity) of cytogenetic
abnormalities did not correlate with EBV infection, pheno-
type, clonality, or clinical outcome (Table 3). Of interest,
clonal chromosomal abnormalities were detected in 4 PTLD
(1 IM-like lesion, 1 HL, 1 P-PTLD, 1 M-PTLD) that were
polyclonal by flow cytometry and/or did not show a clonal
band by PCR analysis, highlighting the utility of cytogenetic
analysis in detecting clonal proliferations in PTLD.4. Discussion
Infectious mononucleosis–like lesions and PH are
considered the earliest morphologically recognizable types
of PTLD in the current WHO classification [1], as both
P-PTLD and M-PTLD have been documented in the vicinity
of or at another site concurrently or subsequent to such
Analysis of B-cell PTLD 323lymphoproliferations [26,27]. One of our patients with PH
also developed an M-PTLD (PLL) at the same site. How-
ever, in the absence of any demonstrable increase in risk for
developing more advanced PTLD, some have argued
against inclusion of these lesions as forms of PTLD [5];
an argument perhaps bolstered by the absence of mutations
and/or translocations of oncogenes or tumor suppressor
genes in patients with PH [4]. Epstein-Barr virus infection
has been implicated in the pathogenesis of IM-like lesions
and PH [4,27], although EBV IM-like lesions have been
described [2]. The presence of rare EBER+ cells in our IM-
like lesion could possibly be attributed to the immunosup-
pressed state, suggesting an etiology similar to EBV cases.
The detection of a clonal aberration in an IM-like lesion,
which has also been observed in other types of PTLD, often
in association with other abnormalities (see below) [21,22],
illustrates that genetic aberrations do occur in IM-like
lesions and supports the contention of including these
lesions within the spectrum of PTLD.
Lymphoid tissue of the Waldeyer’s ring is a common site
for FFH [6,7] and PTLD [26], especially in children, which
has been attributed to a greater frequency of primary EBV
infection in these patients. Adenotonsillar FFH has been
proposed to represent an early event in PTLD pathogenesis
[6,7]; however, no PTLD were observed within a period of
5 years after FFH in one study [8]. In our study, 2 patients
developed PTLD after previous FFH. Although clonal
relatedness between FFH and PTLD could not be demon-
strated, the occurrence of early lesions or other types of
PTLD in the vicinity of prior FFH suggests that FFH could
represent the earliest phase of immune activation, which can
progress to more advanced types of PTLD, albeit in a
minority of patients and after a long latency period. This
hypothesis is supported by the report of Lones et al [26]
who described a tonsillar P-PTLD that developed in the
background of FFH. The occurrence of FFH at the same or
different site, after PTLD in 2 of our patients, does not argue
against this proposal, as multiple metachronous PTLD
arising at different sites are not uncommon in transplant
patients [27] and FFH could conceivably be the precursor of
these lymphoproliferations.
We did not find any correlation between EBV infection
and the occurrence of FFH in our patients, suggesting that
FFH posttransplantation is a consequence of chronic
antigenic stimulation in the setting of immune deregulation
rather than EBV infection per se. The occurrence of EBV
PTLD in EBV-seropositive individuals also supports an
important primary role of immune deregulation in the
pathogenesis of PTLD. Minor clonal karyotypic abnormal-
ities were identified in 11.1% of cases of FFH, possibly
arising during florid GC reactions. Similar abnormalities
have also been reported in P-PTLD [18,22] and M-PTLD
[19-22], further supporting a pathogenetic link between FFH
and more advanced forms of PTLD. It has been shown
that synchronous or metachronous PTLD, involving the
same organ or occurring at different sites, can eitherrepresent different, distinct clonal proliferations [28] or
migration of the same neoplastic clone [29]. However, the
time of clonal spread is not known. Our detection of
identical cytogenetic abnormalities in the tonsils and
adenoids of 1 patient with FFH indicated local dissemina-
tion of the abnormal clone, which leads us to speculate that
(at least) regional spread of aberrant clones might occur
early in the evolution of some PTLD.
Cytogenetic abnormalities were also observed in 65% of
our B-cell PTLD (33% of P-PTLD and 75% of M-PTLD), a
higher overall frequency compared to the reports of Poirel
et al [21], who found chromosomal imbalances in 48% of
B-cell PTLD (57% of P-PTLD and 46% of M-PTLD) using
comparative genomic hybridization analysis and Djokic et al
[22], who identified chromosomal abnormalities in 45% of B-
cell PTLD (15% of P-PTLD and 72% of M-PTLD) by
G-banded karyotype analysis. Poirel et al reported a tendency
for EBV PTLD to have more complex chromosomal
abnormalities compared with EBV+ PTLD and a worse
clinical outcome of M-PTLDwith cytogenetic abnormalities.
We did not observe a difference in the cytogenetic complexity
between EBVor EBV+ PTLD or in the clinical outcomes of
patients with PTLD associated with cytogenetic abnormali-
ties compared with patients who had PTLD with normal
karyotypes. This might relate to shorter follow-up, fewer
EBV PTLD, differences in therapy, or most likely an
absence of T-cell PTLD in our series. The latter are more
often EBVand have a more aggressive clinical course [30].
Posttransplant lymphoproliferative disorders with karyo-
typic abnormalities in our series occurred significantly later
compared with those lacking cytogenetic aberrations
(Table 3). Failure to obtain metaphases from neoplastic
lymphocytes could have accounted for the normal karyotype
in some of our PTLD. However, an absence of chromosomal
imbalances in 52% of PTLD by comparative geno-
mic hybridization analysis [21] suggests that subsets of
PTLD could arise by mutations or epigenetic alterations
of oncogenes and tumor suppressor genes or cellular
transformation by oncogenic EBV latency proteins in certain
cases [15,31,32].
A few of the karyotypic abnormalities observed in our
PTLD, including the IM-like lesion, have been previously
reported [16,18-22], although the frequency of various
recurrent abnormalities in our series (chromosomes 1q and
7) differed from those described by Poirel et al [21] (8q24
and 3q gains) and Djokic et al [22] (trisomy 9 and 11).
Epstein-Barr virus–associated PTLD with chromosome
9 and 11 aberrations have also been described by others
[3,18,20] and Thangavelu et al [33] detected trisomy 9 and
11 among other clonal abnormalities in B-cell lymphomas
that developed in severe combined immunodeficiency mice
inoculated with lymphocytes from EBV seropositive indi-
viduals. We only observed insertions or translocations
targeting chromosomal region 11q23-q24 in 1 case each
of P-PTLD, and HL and 9p23 in 1 case of M-PTLD. Of
interest, chromosome 14q32 aberrations were only seen in
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PTLD with a post-GC phenotype. Translocations of MYC
were detected in BL similar to the reports of Djokic et al
[22] and Nelson et al [2] but not in other types of M-PTLD
[21]. Translocations of 3q27 (BCL6) and 18q21 were rare in
our series, consistent with previous reports [2,4,16,21,22].
All the chromosomal abnormalities observed in our cases
of FFH and PTLD have also been described in a variety of
B-NHL occurring in immunocompetent patients [9-13], and
many of the loci involved, including 1q21, 1p36, 3p21,
9p23, and 16p13, are thought to harbor potential oncogenes
or tumor suppressor genes [34-38]. Our findings, however,
highlight differences between PTLD and B-NHL of
immunocompetent individuals. Karyotypic aberrations in
M-PTLD, with few exceptions, were less complex com-
pared to DLBCL of immunocompetent individuals [10,11],
and besides BL, cytogenetic abnormalities associated with
distinct subsets of B-NHL were rarely observed. No
translocation t(14;18) was detected. Gains of chromosomes
X, 2, 7, and 12, and chromosome 1q21 aberrations,
considered common secondary alterations in conventional
B-NHL [11,12,39,40], were either present as isolated
abnormalities or seen in conjunction with few additional
karyotypic aberrations in our PTLD. Moreover, an inferior
outcome for PTLD with trisomy 7 or 12 and chromosome
1q21 abnormalities could not be discerned, contrary to what
has been reported for conventional DLBCL [12,13]. Our
findings, in addition to prior observations [20,22], suggest
an early acquisition of the aforementioned abnormalities in
PTLD and indicate differences in the pathways of cytoge-
netic progression of these lymphoproliferations compared to
conventional B-NHL.
DNA double-strand break repair after somatic hyper-
mutation and class-switch recombination during the GC
reaction, thought to be responsible for chromosome trans-
locations in B-NHL [41], might also lead to chromosomal
translocations in PTLD. In vitro infection of lymphocytes
by EBV has been shown to induce chromosomal mis-
segregration resulting in numerical and structural chromo-
somal abnormalities [42,43], possibly due to genetic
instability of adjacent sites of EBV integration or as a
consequence of oxidative stress [44,45]. We did not identify
any consistent or unique chromosomal aberrations in EBV+
PTLD; however, further studies are warranted to investigate
whether chromosomal abnormalities in certain PTLD are
the consequence of a bhit-and-runQ mechanism of EBV
infection [46] or EBV integration.
In summary, we not only confirm previously reported
cytogenetic abnormalities but also describe novel karyotypic
abnormalities in PTLD. Our data expand the spectrum of
chromosomal aberrations associated with these disorders,
which should serve as a useful adjunct to future whole
genome analyses. The presence of karyotypic abnormalities
was not associated with a worse prognosis and the sequence
of acquisition of chromosomal aberrations in PTLD
appeared different compared to conventional DLBCL. Wealso report karyotypic abnormalities in FFH and early
lesions, which have not been described previously. Our
findings provide cytogenetic validation of the current
WHO classification of PTLD and suggest incorporation
of FFH as the earliest precursor in the stepwise model of
PTLD pathogenesis.References
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